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Abstract
Background: Loss-of-function mutations in SCN5A, the gene encoding Nav1.5 Na
+ channel, are associated with inherited
cardiac conduction defects and Brugada syndrome, which both exhibit variable phenotypic penetrance of conduction
defects. We investigated the mechanisms of this heterogeneity in a mouse model with heterozygous targeted disruption of
Scn5a (Scn5a
+/2 mice) and compared our results to those obtained in patients with loss-of-function mutations in SCN5A.
Methodology/Principal Findings: Based on ECG, 10-week-old Scn5a
+/2 mice were divided into 2 subgroups, one displaying
severe ventricular conduction defects (QRS interval.18 ms) and one a mild phenotype (QRS#18 ms; QRS in wild-type
littermates: 10–18 ms). Phenotypic difference persisted with aging. At 10 weeks, the Na
+ channel blocker ajmaline
prolonged QRS interval similarly in both groups of Scn5a
+/2 mice. In contrast, in old mice (.53 weeks), ajmaline effect was
larger in the severely affected subgroup. These data matched the clinical observations on patients with SCN5A loss-of-
function mutations with either severe or mild conduction defects. Ventricular tachycardia developed in 5/10 old severely
affected Scn5a
+/2 mice but not in mildly affected ones. Correspondingly, symptomatic SCN5A–mutated Brugada patients
had more severe conduction defects than asymptomatic patients. Old severely affected Scn5a
+/2 mice but not mildly
affected ones showed extensive cardiac fibrosis. Mildly affected Scn5a
+/2 mice had similar Nav1.5 mRNA but higher Nav1.5
protein expression, and moderately larger INa current than severely affected Scn5a
+/2 mice. As a consequence, action
potential upstroke velocity was more decreased in severely affected Scn5a
+/2 mice than in mildly affected ones.
Conclusions: Scn5a
+/2 mice show similar phenotypic heterogeneity as SCN5A-mutated patients. In Scn5a
+/2 mice,
phenotype severity correlates with wild-type Nav1.5 protein expression.
Citation: Leoni A-L, Gavillet B, Rougier J-S, Marionneau C, Probst V, et al. (2010) Variable Nav1.5 Protein Expression from the Wild-Type Allele Correlates with the
Penetrance of Cardiac Conduction Disease in the Scn5a
+/2 Mouse Model. PLoS ONE 5(2): e9298. doi:10.1371/journal.pone.0009298
Editor: Maurizio C. Capogrossi, Istituto Dermopatico dell’Immacolata, Italy
Received September 22, 2009; Accepted February 1, 2010; Published February 19, 2010
Copyright:  2010 Leoni et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Agence Nationale de la Recherche, Paris, France (ANR-05-PCOD-037-01 for FC; ANR-05-MRAR-028 for JJS
and DE), the Fondation Leducq, Paris, France (DE, JJS, AAW), the Netherlands Heart Foundation, Den Haag, The Netherlands (2003/B195 for AAW), the National
Institutes of Health, Bethesda, Maryland, United States of America (NIH R01 HL083422 for PJM) and the Swiss National Science Foundation, Bern, Switzerland
(310000-120707 for HA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: flavien.charpentier@nantes.inserm.fr
{ Deceased.
Introduction
The cardiac voltage-gated Na
+ channel Nav1.5, encoded by
SCN5A gene, determines the upstroke velocity of the action potential
and, in conjunction with gap junction channels and the organization
of the collagenous skeleton, controls the propagation of the cardiac
electrical impulse. Loss-of-function mutations of SCN5A are associ-
ated to the inherited form of progressive cardiac conduction defect
[1,2] (PCCD) and to the Brugada syndrome (BrS) [3–5]. In patients
with inherited PCCD, the conduction of the cardiac impulse is
abnormallyslowandbecomesprogressivelyslowerwithagingleading
ultimately to atrioventricular block and pacemaker implantation in
the elderly [2]. The presence of conduction defects is also one striking
feature of BrS SCN5A-mutation carriers [6,7]. As for most inherited
electrical cardiac diseases, penetrance of the defect caused by SCN5A
haploinsufficiency is variable among carriers of the same mutation,
with patients showing severe conduction alterations and others
exhibiting an almost normal phenotype [2]. This demonstrates that
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, factors independent of the morbid gene exert considerable influence
on outcome of the inherited ‘‘channelopathy’’. One obvious
possibility in humans is the contribution of ‘‘modifier genes’’, which
could control expressivity of the monogenic defect [8].
A mouse model with targeted disruption of Scn5a has been
established [9]. In previous works [10,11], we showed that
heterozygous Scn5a deficient (Scn5a
+/2) mice convincingly recapit-
ulate PCCD phenotype including progressive impairment of atrial
and ventricular conduction with aging. Because progressive decline
in conduction velocity is also associated with myocardial rearrange-
ments and fibrosis, we provided the first demonstration that an
isolated ion channel defect can lead to myocardial structural
anomalies [10]. In the present study, we demonstrate that: (i) the
expression of the conduction anomalies is variable among inbred
Scn5a
+/2 mice; (ii) Scn5a
+/2 mice with severe conduction defects
(severe phenotype) exhibit more myocardial rearrangements with
aging than mice with mild conduction defects (mild phenotype); (iii)
old mice with a severe, but not with a mild phenotype, have a
markedly reduced conduction reserve and show spontaneous
ventricular arrhythmias; (iv) similarly, symptomatic BrS patients
carrying SCN5A mutations have more pronounced conduction
slowing than asymptomatic patients; and, (v) in mice, the expression
of the phenotype correlates with the ability of the normal allele to
produce at the post-transcriptional level variable amount of
functional Nav1.5 channel proteins.
Results
Heterogeneity of the Intraventricular Conduction Defect
in Scn5a
+/2 Mice
Young adult (10–12 week-old) Scn5a
+/2 mice were investigated
for their ventricular conduction parameters. Figure 1A shows
representative ECG recordings from a WT and two Scn5a
+/2 mice.
The two Scn5a
+/2 mice clearly differed since one exhibited a
markedly prolonged QRS complex whereas the other had a
relatively normal one. Figure 1B displays the QRS interval
distribution in 84 WT littermates and 136 Scn5a
+/2 young adult
mice. Statistical analysis showed that the QRS interval duration was
not normally distributed in the Scn5a
+/2 population but distributed
according to two subgroups, (i) one with a severe conduction
phenotype (QRS.18 ms; mean QRS=2260 ms; range 19–26 ms;
n=63), and (ii) the other with a mild conduction phenotype
(QRS#18 ms; mean QRS=1560 ms; range 12–18 ms; n=73;
p,0.05 versus WT and severe phenotype). In the WT littermate
population, QRS duration ranged from 10 to 18 ms (mean
QRS=1360 ms). Each group (WT, mild and severe) differed
significantly from the two others with p values ,0.001. Phenotype
severityinScn5a
+/2micewasnotinfluencedbygender(male/female
ratio: 43/30 and 31/32 in mice with mild and severe conduction
defects, respectively; NS). Moreover, among the 25 litters in which
all Scn5a
+/2 mice have been phenotyped, the average proportion of
mice with mild conduction defects was 0.5360.05 (NS versus
theoretical proportion of 0.5). In 2 litters, all Scn5a
+/2 mice had
mild conduction defects (2 and 3 mice, respectively). In 2 others, all
Scn5a
+/2 mice had, in contrast, severe conduction defects (3 mice in
each). Thus, based on the QRS duration, we distinguished 3 groups
of mice: WT mice, Scn5a
+/2 mice with a mild phenotype, i.e. with a
small QRS prolongation, and Scn5a
+/2 mice with a severe
phenotype, i.e. with a marked QRS prolongation.
Subpopulations of these 3 groups were included in a
longitudinal study conducted up to the age of 80 weeks. There
was a progressive increase in QRS interval with age in WT and
Scn5a
+/2 mice, although this increase was slightly more pro-
nounced in Scn5a
+/2 mice, thus confirming previous results
Figure 1. Variable degrees of ventricular conduction defects in Scn5a
+/2 mice. A. Representative lead I ECGs from 10 week-old wild-type (WT)
mice and Scn5a
+/2 mice with mild and severe conduction defects. Scale bar, 100 ms. B. Distribution of QRS interval duration with corresponding Gaussian
fitsin 10 week-old WT mice (whitebars) and Scn5a
+/2mice with mild (grey bars) andsevere(blackbars)phenotype. C.Effectsofage(X-axis)onQRSinterval
duration (Y-axis) in WT mice (open symbols) and Scn5a
+/2 mice with mild (filled circles) and severe (filled triangles) phenotype. See Table 1 for statistics.
doi:10.1371/journal.pone.0009298.g001
Scn5a
+/2 Mouse Phenotype
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+/2 mice, the difference in
phenotype was maintained over time: each mouse remained in
its initial group. Atrial and atrioventricular conduction (as
evaluated respectively by P wave and PR interval durations) were
similar in the two groups of Scn5a
+/2 mice and significantly slower
than in WT mice (Table 1).
Reduced Conduction Reserve in Scn5a
+/2 Mice and
Patients with SCN5A Mutations with a Severe Phenotype
To estimate their conduction reserve, we challenged young (10
weeks) and old (.53 weeks) Scn5a
+/2 mice with the Na
+ channel
blocker ajmaline (20 mg/kg i.p.). As shown in Figure 2, in young
mice, the effects of ajmaline on the QRS interval were modest and
similar in the two subgroups of Scn5a
+/2 mice (+10.462.0 ms
versus +10.461.2 ms in mice with mild and severe phenotype,
respectively). In old mice, ajmaline prolonged more the QRS
interval in animals with a severe phenotype (+12.060.8 ms) than
in animals with a mild phenotype (+9.660.7 ms; p,0.05).
These mouse data were similar to the results of ajmaline tests
performed in patients from Nantes cohort diagnosed with either
PCCD or BrS and carrying mutations on SCN5A gene. These
patients were separated in two groups based on the duration of
QRS interval under baseline conditions: one with mild conduction
defects (baseline QRS#108 ms) and one with severe conduction
defects (QRS.108 ms; see methods section for the cutoff value
definition). As shown in Figure 2B, the ajmaline-induced QRS
prolongation in aged patients was more pronounced in those with
severe conduction defects under baseline conditions (+5567 ms)
than in those with mild conduction defects (+3465 ms; p,0.05).
In contrast, no statistical difference was seen in the younger
patients.
Thus, the conduction reserve is reduced with aging both in mice
and humans with markedly prolonged QRS interval.
Extensive Cardiac Fibrosis in the Ventricular Myocardium
of Scn5a
+/2 Mice with a Severe Phenotype
Previously, we showed that heterozygous Scn5a invalidation in
mouse produces ventricular rearrangements and fibrosis with
aging [10,11]. We also showed that two transcription factors, Atf3,
a stress-inducible gene, and Egr1, an early growth response gene,
were up-regulated with aging in Scn5a
+/2 mice. Ventricular
sections were evaluated for the presence of fibrosis in 8363
week-old mice. The investigator was blinded to genotype and
phenotype. Scn5a
+/2 mice with a severe phenotype were
characterized by extensive fibrosis located in the left ventricular
free wall and intraventricular septum (Figure 3A). In contrast,
fibrosis in Scn5a
+/2 mice with a mild phenotype when present was
restricted to small areas. Semi-quantitative assessment of cardiac
Table 1. ECG characteristics of wild-type (WT) and Scn5a
+/2 mice with mild and severe phenotype.
n Age (weeks) RR (ms) P (ms) PR (ms) QRS (ms) QT (ms) QTc
WT 16 11601 2 8 631 5 603 5 611 4 616 4 615 8 61
14 31601 2 2 631 6 613 4 611 6 616 0 625 4 61
14 50611 2 2 631 6 613 5 611 6 615 8 615 3 61
12 81631 1 5 61
111 15613 4 611 6 615 8 61
1 5461
Mild Scn5a
+/2 20 12611 3 5 631 8 61** 3961*** 15606 7 615 8 61
16 31601 2 7 621 8 613 9 61*** 1860**
11 6162
11 5461
11
16 49611 3 0 631 8 60* 4061*** 1861**
111 6161
11 5361
11
87 8 651 3 2 62** 1961* 4262*** 2062***
111 6662** 5761
Severe Scn5a
+/2 17 11611 4 2 64*** 1860* 3961*** 2260***
{ 6961* 5961
17 32601 2 8 62
11 1961* 3861*** 2360***
{ 6361
11 5561
17 50621 2 4 62
111 1860*** 3961*** 2460***
{ 6261
11 5661
10 80631 2 8 62* 1961** 4361***
11 2561***
{11 6862*** 5961*
Abbreviations: n, number of animals per group; RR, RR interval duration; P, P wave duration; PR, PR interval duration; QRS, QRS complex duration; QT, QT interval
duration; QTc, corrected QT interval duration.
Data are mean 6 sem. *, **, ***, p,0.05, p,0.01 and p,0.001 respectively versus WT (matching age);
{,p ,0.001 versus Mild (matching age);
1,
11,
111,p ,0.05, p,0.01
and p,0.001 respectively versus youngest age in each group.
doi:10.1371/journal.pone.0009298.t001
Figure 2. Variable effects of Na
+ channel blockade in Scn5a
+/2
mice and SCN5A-mutated patients. Ajmaline-induced increase in
QRS interval (Y-axes) in 10 week- and .53 week-old WT (n=11 and
n=10; open bars), mildly (n=10 and n=10; grey bars) and severely
(n=11 and n=10; black bars) affected Scn5a
+/2 mice (left panel), and in
young (6–31 years; mean=22 years) and older (41–61 years; mean=50
years) non-mutated (n=18 and n=17, open bars) and SCN5A-mutated
patients with either mild (n=12 and n=11; grey filled bars) or severe
(n=7 and n=12; black filled bars) QRS interval prolongation (right
panel). *, ***, p,0.05 and p,0.001 respectively versus WT mice or non-
mutated patients. {,p ,0.05 versus Scn5a
+/2 mice or SCN5A-mutated
patients with a mild phenotype. The difference between old mildly
affected mice and old WT mice did not reach significance (p=0.07).
Same comment for the older patients.
doi:10.1371/journal.pone.0009298.g002
Scn5a
+/2 Mouse Phenotype
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+/2 mice with
severe phenotype (n=8; p,0.05 versus WT), 0.6060.40 in
Scn5a
+/2 mice with mild phenotype (n=5) and 0.2560.25 in
WT mice (n=4). No fibrosis was observed in the right ventricular
outflow tract region of Scn5a
+/2 mice with a severe phenotype (not
shown). The transcription factors Atf3 and Egr1 were exclusively
over-expressed in old Scn5a
+/2 mice with a severe phenotype
(Figure 3B).
Ventricular Arrhythmias in Scn5a
+/2 Mice with a Severe
Phenotype and Wider QRS Interval in Symptomatic
SCN5A-Related BrS Patients
With aging, Scn5a
+/2 mice with a severe phenotype had an
increased propensity to develop spontaneous ventricular arrhyth-
mias under anesthesia (5/10) in comparison to Scn5a
+/2 mice with
a mild phenotype (0/8; p,0.05) and WT mice (0/12; p,0.05).
The severity of the arrhythmias ranged from ventricular extra-
systoles to salvoes of ventricular tachycardia (Figure 4).
Patients from Nantes database with SCN5A-related BrS were
pooled with their counterparts from Amsterdam database. Symp-
tomatic patients, defined as having a clinical history of collapses,
syncopes, documented ventricular tachycardia (and/or fibrillation)
or aborted sudden death, were characterized by a longer QRS
interval than asymptomatic patients (Table 2).
Differential Transcriptional Remodeling between Mild
and Severe Phenotype Scn5a
+/2 Mice
We then investigated the molecular mechanisms potentially
accounting for variable penetrance in Scn5a
+/2 mice. We first
hypothesized that molecular remodeling of ion channel gene
expression could variably modulate the deficit. Figure 5 shows
variations of expression of 46 ion-channel subunits in the ventricles
of 10 week-old Scn5a
+/2 mice relative to their expression in WT
littermates. Nav1.5 transcripts were similarly down-regulated by
almost 50% in Scn5a
+/2 mice with both mild and severe phenotype,
showing that the phenotype heterogeneity was not due to
differential transcription of the WT Scn5a allele. Ion channel
remodeling in Scn5a
+/2 mice was limited to 10 genes. Among them,
4 were moderately up-regulated in both groups of Scn5a
+/2 mice
including ankyrin-B, an anchoring protein involved in ion channel
(including Nav1.5) and transporter targeting [12,13]. Few genes
were differentially regulated among the Scn5a
+/2 mice. Five were
up-regulated only in severely affected Scn5a
+/2 mice, including
genes encoding the Na
+ channel a-subunit Nav1.3, the T-type Ca
2+
channel a-subunit Cav3.2 and connexin 37. Finally, Kcne1, which
encodes KvLQT1 b-subunit, was up-regulated only in mice with
mild phenotype. No gene expression (other than Scn5a) was
Figure 3. Variable levels of fibrosis in Scn5a
+/2 mice. A. Sirius red
staining of ventricle from 85 week-old WT, mildly and severely affected
Scn5a
+/2 mice. Fibrosis appears in red. A score of 0 was attributed to
the WT mouse shown, 1 to the mild Scn5a
+/2 mouse and respectively 2
and 3 to left and right severe Scn5a
+/2 mice. B. Atf3 and Egr1 mRNA
ventricular levels (in arbitrary units) in WT (open bars), mildly (grey bars)
and severely (black bars) affected Scn5a
+/2 mice as a function of age.
***, p,0.001 versus WT and mild.
doi:10.1371/journal.pone.0009298.g003
Figure 4. Cardiac arrhythmias in Scn5a
+/2 mice with severe phenotype. Representative episodes of spontaneous ventricular arrhythmias
recorded in two different Scn5a
+/2 mice with a severe phenotype under anesthesia. An ECG recorded in an age-matched WT mouse is given for
comparison. Scale bar, 500 ms.
doi:10.1371/journal.pone.0009298.g004
Scn5a
+/2 Mouse Phenotype
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pumps and exchangers was not altered.
Reduced Nav1.5 Protein Expression and INa Density in
Scn5a
+/2 Mice with a Severe Phenotype
We then investigated Nav1.5 protein expression. Investigators
were blinded to the genotype and phenotype for all the
experiments presented below.
In young Scn5a
+/2 mice, global Nav1.5 protein was reduced by
5064% in ventricular lysates of animals with a severe phenotype
versus WT littermates (p,0.001) and by only 2167% for animals
with a mild phenotype (p,0.05 versus severe phenotype, NS versus
WT; Figure 6).
At the single cell level, immunofluorescence and confocal
imaging experiments demonstrated that Nav1.5 staining intensity
in intercalated discs was reduced by 4264% in myocytes from
mice with severe phenotype (66 cells from 3 mice; p,0.01 versus
WT), but only by 3062% for mice with mild phenotype (60 cells
from 3 mice; p,0.05 versus severe, p,0.01 versus WT; Figure 6C).
Accordingly, the INa density was 28% larger in mice with a mild
phenotype (5967 pA/pF; 18 cells from 4 mice) than in mice with
a severe phenotype (4664 pA/pF; 21 cells from 4 mice; Figure 7)
although this difference did not reach significance (p=0.08). For
comparison, amplitude of INa in WT mice was 10367 pA/pF (16
cells from 4 mice). In summary, the three independent techniques
indicated a less severe reduction of Nav1.5 proteins in mice with a
mild phenotype than in mice with a severe phenotype. We also
observed a shift towards more positive voltage values of steady-
state inactivation and activation curves in Scn5a
+/2 mice versus WT
mice (Table 3). However, no difference was observed among the
Scn5a
+/2 mice.
The decrease in INa induced a moderate (11–15%) non-
significant decrease in maximum upstroke velocity (Vmax)o f
ventricular action potentials in Scn5a
+/2 mice with mild
conduction defects (Figure 8). In contrast, Vmax was significantly
decreased by 33–42% in Scn5a
+/2 mice with a severe phenotype.
They also exhibited a significant decrease in action potential
amplitude. Other action potential parameters did not differ among
the groups.
Discussion
The main findings of the present study are: (i) Scn5a
+/2 mice
exhibit variable penetrance of the conduction deficit, as do patients
with SCN5A loss-of-function mutations [2,6]; (ii) Scn5a
+/2 mice with
severe ventricular conduction defects, exhibit more myocardial
rearrangements with aging than mice with a mild phenotype; (iii)
only old mice with a severe phenotype have a markedly reduced
conduction reserve and show spontaneous ventricular arrhythmias;
(iv) symptomatic BrS patients carrying SCN5A mutations have more
pronounced conduction slowing than asymptomatic patients; and
(v) the expressivity of the conduction deficit in Scn5a
+/2 mice is
correlated with the expression level of WT functional Nav1.5
proteins. Mice with a severe phenotype correspond to the expected
haploinsufficient situation since they exhibit <50% reduction in
Nav1.5 protein expression whereas Nav1.5 reduction in mice with a
mild phenotype was less pronounced.
Because distribution of QRS intervals in the Scn5a
+/2 mouse
population is bimodal, we speculate that a compensatory
mechanism is active in the mild-phenotype subgroup but inactive
in the severe-phenotype subgroup. Such a mechanism governs the
severity of the conduction slowing that in turn commands the
extent of myocardial rearrangements and fibrosis, confirming our
hypothesis of a direct link between ventricular conduction defects
and fibrosis [10]. Moreover, that occurrence of large areas of
fibrosis in mice with a severe phenotype was preceded by large
overexpression of Egr1 and Atf3 in these mice and not in mice with
a mild phenotype, which have much less fibrosis, confirms our
hypothesis that these transcription factors are involved in
myocardial rearrangements [10].
Molecular Mechanism for Variable Penetrance of the
Phenotype in the Mouse
Because cardiac conduction relies not only on Na
+ current, but
also on cellular coupling and myocardial architecture, different
hypotheses could be evoked to explain Scn5a
+/2 mice phenotypic
variability. Variable myocardial rearrangement was not expected
to explain phenotypic variability since heterogeneity is already
present in young adult mice whereas fibrosis occurs only in older
mice [10,11]. We first hypothesized that Nav1.5 invalidation could
lead to altered expression of other ion channel subunits and of
connexins that would vary among mice. Our data indicate that ion
channel remodeling was limited to only a few genes. Among them,
some were indeed differentially regulated depending on the
phenotype severity. However, the contribution of these genes to
the phenotype is unlikely since they are either not or weakly
expressed in adult mouse ventricle. For instance, the cardiac
expression of connexin-37 is restricted to endothelial cells [14].
Overexpression of the mRNA of neuronal Na
+ channel, Nav1.3,
and T-type Ca
2+ channel, Cav3.2, may result from a feedback
mechanism compensating for the larger conduction deficit of mice
with a severe phenotype. In any case, the putative resulting
increase in Na
+ and T-type Ca
2+ currents would improve
conduction and not further deteriorate it. The consequences of
KvLQT1 b-subunit (Kcne1 gene) overexpression in Scn5a
+/2 mice
with a mild phenotype are also difficult to predict. In adult mice,
Kcne1 cardiac expression is restricted to the conduction system
[15]. Based on studies performed on Langendorff-perfused hearts
showing that targeted disruption of Kcne1 can alter ventricular
conduction velocity [16], one could speculate that Kcne1
overexpression in Scn5a
+/2 mice with a mild phenotype could
contribute to their shorter QRS interval. However ECG
recordings in Kcne1 knockout mice did not display any alteration
of the QRS interval [15], suggesting that this protein is not playing
a major role in cardiac impulse propagation.
Table 2. ECG characteristics of asymptomatic (n=84) and symptomatic (n=24) SCN5A-mutated Brugada patients.
Age (yrs) RR (ms) P (ms) PR (ms) QRS (ms) QT (ms) QTc
Asymptomatic 4162 901618 93631 9 1 641 1 0 62 393634 1 7 63
Symptomatic 4663 915631 97642 0 0 65* 11864* 401664 1 7 67
Same abbreviations as in Table 1.
Data are mean 6 sem. *, p,0.05 versus asymptomatic patients.
doi:10.1371/journal.pone.0009298.t002
Scn5a
+/2 Mouse Phenotype
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was that Scn5a
+/2 mice had variable reduction in Na
+ current.
Scn5a transcript levels were similar in both groups of Scn5a
+/2
mice suggesting the same transcriptional regulation of the WT.
However, Nav1.5 protein amounts and INa were larger in Scn5a
+/2
mice with a mild phenotype. The reason for increased expression
of Nav1.5 protein in mice with a mild phenotype is as yet
unknown. In addition to gene transcription and RNA processing,
the expression of functional Nav1.5 proteins will depend on a series
of complex interacting processes such as protein synthesis,
assembly and post-translational modifications, trafficking to the
sarcolemma, anchoring to the cytoskeleton and regulation of
endocytosis and degradation, which are yet incompletely under-
stood [17,18].
At first glance, QRS variability might appear unexpectedly
large for an inbred mouse strain. It is widely recognized that
environmental, investigator-dependent, and time variables can be
confounding factors influencing the characterization of mouse
Figure 5. Moderate ionic remodeling in Scn5a
+/2 mice. Percentage of variation in ventricular expression (Y-axes) of 46 genes encoding ion
channel subunits (ch) and connexins (Cx) in Scn5a
+/2 mice with mild (grey bars; n=5) and severe (black bars; n=7) phenotype versus WT mice
(n=10). Sub, subunits. *, **, ***, p,0.05, p,0.01 and p,0.001 respectively versus WT; {, {{{,p ,0.05 and p,0.001 respectively versus mild
phenotype.
doi:10.1371/journal.pone.0009298.g005
Scn5a
+/2 Mouse Phenotype
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to explain phenotypic variability of Scn5a
+/2 mice. Indeed, a single
investigator carried out all ECG recordings and analyses.
Moreover, since long-term follow-up studies have shown that the
mice keep their phenotype severity throughout their life, possible
interference with the season or time of the day can be excluded.
Finally, and perhaps more importantly, histological studies,
immunoblot experiments, patch-clamp and microelectrode re-
cordings were performed under blind conditions.
In both groups of Scn5a
+/2 mice, the steady-state inactivation
and activation and curves were shifted towards more positive
voltages than in wild-type mice. To our knowledge, this
phenomenon has not described before. It may be speculated that
a decrease in the number of sarcolemmal Na
+ channels could
trigger changes in the expression/interaction of proteins that
remain to be indentified altering Nav1.5 biophysical properties.
Whatever its mechanism, one consequence of this shift should be
that the fraction of Na
+ channels available for cardiac depolar-
ization is larger in Scn5a
+/2 mice (about 80%) than in wild-type
mice (50%).
Potential Implications in PCCD and Brugada Syndrome
We are not aware of long-term individual follow-up data in
patients with PCCD that would extend over decades. Comparison
between mice and humans is thus difficult to achieve. Our study
points to a key similarity between Scn5a
+/2 mice and loss-of-
function SCN5A mutation human carriers. Young Scn5a
+/2 mice
or patients with markedly prolonged QRS interval have a
conduction reserve similar to Scn5a
+/2 mice or patients with
mildly prolonged QRS interval, but this reserve fades out with
aging. If findings obtained in mouse can be transposed in human,
they suggest that depending on the duration of the QRS complex
at young age, one may predict the evolution of the conduction
disease and requirement for pacemaker in patients with inherited
PCCD. Interestingly, in families with SCN5A-related PCCD, the
phenotype heterogeneity is high at middle age and some old
mutated patients do not develop the disease [2]. In Scn5a
+/2
mouse, decreased conduction reserve is due to fibrosis and
connexin expression remodeling [10,11], which can be considered
Figure 6. Decreased Nav1.5 expression in Scn5a
+/2 mice. A.
Representative Western blots showing the expression levels of Nav1.5 in
WT mice and Scn5a
+/2 mice (mean age=1861 weeks) with a mild or a
severe phenotype. Protein loading was controlled by anti-actin
immunoblotting. B. Quantification of Nav1.5 expression in WT mice
(open bars) and Scn5a
+/2 mice with mild (grey bars) and severe (black
bars) phenotype was performed on Western blots from 10 mice in each
group by normalizing the intensities of the Nav1.5 bands to the actin
bands. ***, p,0.001 versus WT; {,p ,0.05 versus mild Scn5a
+/2 mice. C.
Confocal images of Nav1.5 in ventricular cardiomyocytes isolated from
WT mice (left panel) and Scn5a
+/2 mice with mild (middle panel) and
severe (right panel) phenotype. Scale bar, 20 mm. In Scn5a
+/2 images
presented, a WT cardiomyocyte is also included in the image frame
(yellow arrows) to illustrate the clear difference in WT versus Scn5a
+/2
intercalated disc staining intensities.
doi:10.1371/journal.pone.0009298.g006
Figure 7. Variable INa densities in Scn5a
+/2 single ventricular
cardiomyocytes. A. Representative INa traces (protocol in inset)
obtained from ventricular myocytes in a 12 week-old WT mouse and
Scn5a
+/2 mice with mild and severe phenotype. Horizontal bar, 2 ms;
vertical bar, 40 pA/pF. B. INa density in myocytes from WT and Scn5a
+/2
mice with mild and severe phenotype (4 mice in each group, 4 to 6 cells
for each mouse). **, p,0.01 versus WT mice.
doi:10.1371/journal.pone.0009298.g007
Table 3. INa steady-state activation and inactivation
properties of isolated ventricular myocytes from wild-type
(WT) and Scn5a
+/2 mice with mild and severe phenotype.
WT Mild Scn5a
+/2 Severe Scn5a
+/2
Activation n=12 n=13 n=10
K (mV/e-fold) 5.960.1 6.160.2 5.960.1
V1/2 (mV) 237.661.0 231.262.0* 231.061.3*
Inactivation n=10 n=10 n=10
K (mV/e-fold) 6.460.2 6.860.3 7.060.2
V1/2 (mV) 277.962.5 268.862.5* 268.061.6**
Abbreviations are: n, number of myocytes per group; K, slope factor; V1/2, half-
activation or half-inactivation voltage (see methods section for calculation
procedure).
Data are mean 6 sem. *, **, p,0.05 and p,0.01 respectively versus WT
(Kruskal-Wallis test, Dunn’s post-test).
doi:10.1371/journal.pone.0009298.t003
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However, even if mice and humans present similar phenotypes,
this does not imply that the same pathophysiological mechanisms
are involved.
In old Scn5a
+/2 mice with severe phenotype, fibrosis and
connexin expression remodeling could partly explain the high
incidence of spontaneous ventricular arrhythmias, which were
never observed in mice with a mild phenotype and WT mice.
Indeed, the presence of large areas of fibrosis associated with
connexin-43 redistribution in areas surrounding fibrosis [11] most
likely contributes to the occurrence of reentrant arrhythmias. We
never observed any arrhythmias in younger animals, although ex
vivo experiments had shown that young adult Scn5a
+/2 mice were
more prone than WT mice to develop arrhythmias under
programmed electrical stimulation [9]. This suggests that the
decrease in INa per se is not enough to trigger spontaneous
arrhythmias in mice.
In our cohort, symptomatic SCN5A-related BrS patients were
characterized by more pronounced ventricular conduction defects
than asymptomatic patients. This confirms a recent publication by
Junttila and co-workers [21] and supports further the importance
of conduction defects in Brugada syndrome pathophysiology
[22,23]. Whether the substrate for arrhythmias in SCN5A-related
BrS patients relies essentially on Nav1.5 dysfunction or involves
additional myocardial rearrangements is unclear. Although
structural abnormalities are not detected using routine noninvasive
diagnostic tools, fatty replacement, right ventricular fibrosis,
myocyte degeneration and apoptosis have been reported [23–25].
Moreover, a boy with compound heterozygosity for two SCN5A
mutations exhibited severe degenerative changes in the ventricular
conduction system [26]. Taken together, studies in patients and in
Scn5a
+/2 mice strongly suggest that a primary abnormality in
Nav1.5 channel may lead to cellular damage. On this basis,
arrhythmias may occur when a sufficient degree of myocardial
rearrangement has been reached. This would explain why, in the
context of an inborn defect, several years (in humans) or months (in
mice) might elapse before the first arrhythmic event.
Materials and Methods
Ethics Statement
All the animal experiments were performed in the animal
facility (Unite ´ de The ´rapeutique Expe ´rimentale) and the Inserm UMR915
laboratory which have been accredited by the French Ministry of
Agriculture. Experimental procedures were approved by the
regional ethic committee (CREEA – Pays de la Loire).
Studies involving human participants were conducted according
to the French and Dutch guidelines for genetic research. All tests
that were performed were approved by the medical ethical review
committees of the two hospitals involved: Academic Medical
Center, Amsterdam, The Netherlands; Centre Hospitalo-Universitaire,
Nantes, France (CCPPRB des Pays de la Loire). Written informed
consent was obtained from the patients.
Electrocardiography in Mouse
All mice with 129/Sv genetic background were bred at l’institut
du thorax (Nantes, France) and genotyped by polymerase chain
reaction (PCR) as previously described [9]. All experiments were
performed on age-matched wild-type (WT) and heterozygous
littermates.
Six-lead ECGs were recorded on mice anesthetized with
etomidate (25 mg/kg i.p.) and analyzed as previously described
[10]. Pharmacological challenge with the Na
+ channel blocker
ajmaline (20 mg/kg, i.p.) was performed in 10 and .53 week-old
mice. QRS interval lengthening was assessed 10 minutes after
injection.
ECG Recordings and Clinical Data from Patients with
SCN5A Mutations
The study was conducted according to the French and Dutch
guidelines for genetic research. All tests that were performed were
approved by the medical ethical review committees of the two
hospitals involved: Academic Medical Center, Amsterdam, The
Netherlands; Centre Hospitalo-Universitaire, Nantes, France (CCPPRB
des Pays de la Loire). Written informed consent was obtained from
the patients.
A first study was aimed at evaluating the effects of ajmalin on
conduction defects in patients from the Nantes database carrying
SCN5A loss-of-function mutations. The cohort included families
with SCN5A mutations leading to Brugada syndrome only and
families with SCN5A mutations leading to either progressive
cardiac conduction defects (PCCD) or Brugada syndrome
[27]. These patients had a median QRS interval duration of
108612 ms. This value was used as a cut-off to discriminate
patients with minor conduction defects (QRS#108 ms; mild
phenotype) or major conduction defects (QRS.108 ms; severe
phenotype). Non-mutation carrier siblings served as controls. Two
age groups were then distinguished, 6–31 years and 41–61 years.
In the 6–31 year-old patient group (mean value: 2162 years;
n=19), patients with a mild phenotype had a mean QRS duration
Figure 8. Action potential amplitude (AP amp; top) and
maximum upstroke velocity (Vmax; bottom) as a function of
pacing frequency. White circles, wild type mice (n=7); black circles,
Scn5a
+/2 mice with a mild phenotype (n=6); black triangles, Scn5a
+/2
mice with a severe phenotype (n=5). At 800 bpm, 4 preparations from
Scn5a
+/2 mice with a severe phenotype were periodically (for 1 of them)
or continuously (for the 3 others) in 2:1 conduction block. *, p,0.05.
doi:10.1371/journal.pone.0009298.g008
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phenotype had a mean QRS duration of 13067 ms (110–
158 ms; n=7; p,0.001 versus mild). In the older patient group
(5161 years; n=23), patients with a mild phenotype had a mean
QRS interval of 9462 ms (80–107 ms; n=11) whereas patients
with a severe phenotype had a QRS of 12264 ms (112–160 ms;
n=12; p,0.001 versus mild). All patients were challenged with
ajmaline according to current guidelines [28].
In a second study, clinical data from patients carrying SCN5A
mutations leading to Brugada syndrome from the Nantes and
Amsterdam databases were pooled (n=108). This mixed database
was used to discriminate symptomatic and asymptomatic patients.
Symptomatic patients had a clinical history of collapses, syncopes,
documented ventricular tachycardia (and/or fibrillation) or
aborted sudden death. Baseline QRS interval duration were
compared between symptomatic and asymptomatic patients.
Histology
Cardiac arrest was induced in sedated mice (etomidate, 30 mg/
kg i.p.) with intravenous infusion of 10% KCl. After excision,
hearts were rinsed in saline solution and fixed by immersion in
10% formalin for 24h. Then, gross transverse sections were cut
from the base to the apex and embedded in paraffin. Paraffin
sections were stained with hematoxylin-eosin to assess any
myocyte necrosis or interstitial inflammation or Sirius red to
assess interstitial and scar fibrosis. Serial sections were cut to track
the ventricular outflow tract. Semi-quantitative assessment of
fibrosis was determined based upon the extent and the number of
interstitial fibrosis and scar foci (and scored 0 to 3).
TaqMan Real-Time RT-PCR
For Atf3 and Egr1 genes, Taqman real-time RT-PCR was
performed as previously described [10]. The ion channel gene
expression patterns of ventricular preparations from WT and
Scn5a
+/2 mice were characterized with TaqMan Low Density
Arrays (Applied Biosystems, Foster City, CA) in a two-step RT-
PCR process. The genes selected for their cardiac expression
encode 68 ion channel a- and auxiliary subunits, 7 proteins
involved in calcium homeostasis, 5 transcription factors, specific
markers of cardiac regions, vascular vessels, neuronal tissue,
fibroblasts, inflammation and hypertrophy, and 4 endogenous
control genes used for normalization. First strand cDNA was
synthesized from 220 ng of total RNA using the High-Capacity
cDNA Archive Kit (Applied Biosystems). Experimental procedure
and data analysis were performed as previously described [29].
Protein Isolation and Western Blot
After excision, hearts were rapidly frozen in liquid nitrogen and
stored at 280uC. Frozen mouse ventricle was transferred into lysis
buffer containing (in mmol/L): trishydroxyaminomethane (TRIS),
50 (pH 7.5); NaCl, 150; ethylenediaminetetra-acetic acid (EDTA),
1; phenylmethylsulfonyl fluoride (PMSF), 1; CompleteH protease
inhibitor cocktail from Roche Applied Science (Basel, Switzer-
land). Tissues were then homogenized using a Polytron. Triton
Tx-100 was added to a final concentration of 1% and
solubilization occurred by rotating for 1 h at 4uC. The soluble
fraction from a subsequent 15-min centrifugation at 13,000 g
(4uC) was used for the experiments. In order to load each lane of
the SDS-page with equivalent amounts of total proteins, the
protein concentration of each lysate was measured in triplicate by
Bradford assay using a BSA standard curve.
Polyclonal anti-Nav1.5 antibody (ASC-005) was purchased from
Alomone (Jerusalem, Israel) and rabbit anti-actin antibody (A
2066) was purchased from Sigma (Buchs, Switzerland). The
immunoblot signals were visualized using enhanced chemilumi-
nescence (ECL). Densitometric analyses of ECL films were
performed using QuantityOne Software (BioRad, Hercules,
California, USA). Bands were manually selected using the volume
tool. For each band, the background was subtracted and the signal
intensity was normalized to actin.
Immunofluorescence Experiments on Isolated
Cardiomyocytes
Cardiomyocytes were washed with phosphate-buffered saline
(PBS,pH 7.4)andfixed in2%paraformaldehyde(37uC).Cellswere
blocked/permeabilized in PBS containing 0.075% Triton X-100
and 3% fish oil gelatin, and incubated in primary antibody,
(polyclonal Nav1.5 antibody) overnight at 4uC [30]. Following
washes (PBS plus 0.1% Triton X-100), cells were incubated in
secondary antibody (Alexa 568; Molecular Probes) for 8 hours at
4uCand mounted usingVectashield (Vector).Images werecollected
on a Zeiss 510 Meta confocal microscope (63 power oil immersion,
1.4 NA, 1.0 Airy Units) using Carl Zeiss Imaging software. Volocity
Classification and LSM510 software (Zeiss) were used to measure
pixel intensities. The following imaging protocol was adopted. Data
were first collected on WT cardiomyocytes to establish a linear
imaging protocol. All cardiomyocytes were imaged using an
identical imaging protocol (LSM510 ‘re-use’ function to ensure
consistency in pinhole diameter, brightness, contrast, and laser
intensity). Since Nav1.5 is primarily expressed in the intercalated
disc region [31,32], we determined the mean staining intensity for 3
intercalated disc line scans per myocyte. For each group, at least 60
myocytes from 3 different mice were analyzed.
Isolation of Cardiac Myocytes and Patch Clamp
Experiments
Ventricular myocytes were isolated as previously described [33].
Whole-cell configuration of the patch-clamp technique was used to
record INa. Experiments were performed at room temperature
(22–23uC), using a VE-2 (Alembic Instruments, Canada) amplifier
allowing the recording of large Na
+ currents. Pipettes (tip
resistance of 1–2 MV) were filled with a solution containing (in
mmol/L): CsCl, 60; Cesium asparte, 70; CaCl2, 1; MgCl2,1 ;
HEPES, 10; EGTA, 11; Na2ATP, 5 (pH was adjusted to 7.2 with
CsOH). Myocytes were bathed with a solution containing (in
mmol/L): NaCl, 10; NMDG-Cl, 120; CaCl2, 2; MgCl2, 1.2; CsCl,
5; HEPES, 10; Glucose 5 (pH was adjusted to 7.4 with CsOH).
Holding potentials were 2120 mV and INa densities (pA/pF) were
obtained by dividing the peak INa by the cell capacitance. Peak
currents were measured during a voltage-clamp protocol.
To quantify the voltage dependence of steady-state activation
and inactivation, data from individual cells were fitted with the
Boltzmann relationship, y (Vm)=1/1+exp[(Vm2V)/K], in which
y is the normalized current or conductance, V is the voltage at
which half of the available channels are inactivated, K is the slope
factor, and Vm is the membrane potential. The voltage
dependence of inactivation was determined by measuring current
in response to pulses (20 ms) to 220 mV that had been preceded
by 500-ms pulses applied in a series of 5-mV incremental voltages
from 2130 mV to 220 mV.
Microelectrode Studies
Seven wild-type (WT) and 11 Scn5a
+/2 (6 with a mild phenotype
and 5 with a severe phenotype) adult mice of either sex were killed
by cervical dislocation. The hearts were quickly removed and
immersed in a cool modified Tyrode solution containing (in
mmol/L): NaCl, 108; NaHCO3, 25; NaH2PO4, 1.8; KCl, 27;
Scn5a
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95% O2-5% CO2 gas mixture (pH 7.3). Preparations were
mounted in a tissue bath chamber, the endocardial surface facing
up and superfused with an oxygenated (95% O2-5% CO2) Tyrode
solution warmed to 3760.5uC and containing (in mmol/L): NaCl,
120; NaHCO3, 27; NaH2PO4, 1.2; KCl, 5.4; MgCl2, 1.2; CaCl2,
1.8; glucose, 10 (pH 7.4). Transmembrane recordings were
obtained using standard methods. The tissues were allowed to
recover for at least one hour before the experiments started.
During this period, they were paced at a frequency of 300 beat per
minute (bpm) by bipolar stimulation through Teflon-coated silver
wire electrodes. Stimulus pulse width was 1 ms and amplitude was
twice diastolic threshold. The preparations were then paced at
frequencies increasing from 200 to 800 bpm. Action potentials
characteristics were measured at steady state for each frequency.
Statistical Analysis
Data are expressed as mean 6 SEM. Statistical analysis was
performed with Student t-test, Kruskall-Wallis test and one- or
two-way analysis of variance completed by a Tukey test when
appropriate. The Fisher Exact test was used for the statistical
analysis of proportions of mice with arrhythmias. A value of
p,0.05 was considered significant.
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